Bao Pharma Maintains Stable Share Capital in March 2026, Reaffirms Public-Float Compliance

Bulletin Express04-02

Shanghai Bao Pharmaceuticals Co., Ltd. (Bao Pharma) filed its monthly return for the period ended 31 March 2026, showing no movement in either authorised or issued share capital.

• Capital structure unchanged – Authorised/registered share capital remained at RMB 65.20 million, comprising 154.33 million H-shares and 171.65 million domestic shares, each with a par value of RMB 0.20. – Issued share capital mirrored the authorised totals, with 0 treasury shares outstanding.

• No corporate actions during the month The company reported no share issuances, cancellations, repurchases, options, warrants, convertibles, or other equity arrangements.

• Public-float requirement met Bao Pharma confirmed compliance with the Main Board’s minimum 25% public-float rule for its H-shares as at 31 March 2026.

The filing was signed by Executive Director Liu Yanjun on 2 April 2026.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1164470710?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-04-02 16:45","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1164470710","market":"us","top_or_hot":-1,"title":"Bao Pharma Maintains Stable Share Capital in March 2026, Reaffirms Public-Float Compliance","media":"Bulletin Express","content":"<p>Shanghai Bao Pharmaceuticals Co., Ltd. (Bao Pharma) filed its monthly return for the period ended 31 March 2026, showing no movement in either authorised or issued share capital.</p>\n<p>• Capital structure unchanged  \n– Authorised/registered share capital remained at RMB 65.20 million, comprising 154.33 million H-shares and 171.65 million domestic shares, each with a par value of RMB 0.20.  \n– Issued share capital mirrored the authorised totals, with 0 treasury shares outstanding.</p>\n<p>• No corporate actions during the month  \nThe company reported no share issuances, cancellations, repurchases, options, warrants, convertibles, or other equity arrangements.</p>\n<p>• Public-float requirement met  \nBao Pharma confirmed compliance with the Main Board’s minimum 25% public-float rule for its H-shares as at 31 March 2026.</p>\n<p>The filing was signed by Executive Director Liu Yanjun on 2 April 2026.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Bao Pharma Maintains Stable Share Capital in March 2026, Reaffirms Public-Float Compliance</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBao Pharma Maintains Stable Share Capital in March 2026, Reaffirms Public-Float Compliance\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2026-04-02 16:45</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Shanghai Bao Pharmaceuticals Co., Ltd. (Bao Pharma) filed its monthly return for the period ended 31 March 2026, showing no movement in either authorised or issued share capital.</p>\n<p>• Capital structure unchanged  \n– Authorised/registered share capital remained at RMB 65.20 million, comprising 154.33 million H-shares and 171.65 million domestic shares, each with a par value of RMB 0.20.  \n– Issued share capital mirrored the authorised totals, with 0 treasury shares outstanding.</p>\n<p>• No corporate actions during the month  \nThe company reported no share issuances, cancellations, repurchases, options, warrants, convertibles, or other equity arrangements.</p>\n<p>• Public-float requirement met  \nBao Pharma confirmed compliance with the Main Board’s minimum 25% public-float rule for its H-shares as at 31 March 2026.</p>\n<p>The filing was signed by Executive Director Liu Yanjun on 2 April 2026.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02659","symbol_name":"宝济药业-B","start_time":0,"source_url":"","article_id":"1164470710","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1164470710","pubTimestamp":1775119505,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"Shanghai Bao Pharmaceuticals Co., Ltd. (Bao Pharma) filed its monthly return for the period ended 31 March 2026, showing no movement in either authorised or issued share capital. • Capital structure...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02659":"宝济药业-B"},"translate_title":"宝药业2026年3月股本保持稳定，重申公众持股量合规","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02659":1},"content_text":"Shanghai Bao Pharmaceuticals Co., Ltd. (Bao Pharma) filed its monthly return for the period ended 31 March 2026, showing no movement in either authorised or issued share capital.\n• Capital structure unchanged  \n– Authorised/registered share capital remained at RMB 65.20 million, comprising 154.33 million H-shares and 171.65 million domestic shares, each with a par value of RMB 0.20.  \n– Issued share capital mirrored the authorised totals, with 0 treasury shares outstanding.\n• No corporate actions during the month  \nThe company reported no share issuances, cancellations, repurchases, options, warrants, convertibles, or other equity arrangements.\n• Public-float requirement met  \nBao Pharma confirmed compliance with the Main Board’s minimum 25% public-float rule for its H-shares as at 31 March 2026.\nThe filing was signed by Executive Director Liu Yanjun on 2 April 2026.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"shareholding,SGX","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.0","shortVersion":"4.42.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1164470710","isCrawlerRequest":true}